Search

Displaying results 1181 - 1190 of 8194 in total
  1. Drug

    Migalastat

    go.drugbank.com/drugs/DB05018
    ApprovedInvestigational

    [L47036,L47057,L4274,L4278] In these patients, migalastat works by stabilizing the body’s dysfunctional alpha-Gal A enzyme so that it can clear the accumulation of glycosphingolipid disease substrate. … [L4274] Migalastat (approved and sold under Amicus Therapeutics' brand name Galafold) is subsequently an oral pharmacological chaperone of alpha-Gal A for the treatment of Fabry disease in adults who

  2. Drug

    Mafenide

    go.drugbank.com/drugs/DB06795
    ApprovedVet approvedWithdrawn

    In November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements

  3. Drug

    Norethisterone

    go.drugbank.com/drugs/DB00717
    ApprovedInvestigational

    L9527,L10301,L10304,L10307] First derived in 1951 in Mexico City, norethisterone was originally intended for use as a remedy for irregular menstruation and endometriosis, and was not marketed for use as an

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesInternational brands: Mini-PE
  4. Drug

    Sodium phosphate, monobasic

    go.drugbank.com/drugs/DB09449
    ApprovedInvestigational

    Sodium phosphate is a saline laxative that is thought to work by increasing fluid in the small intestine. It usually results in a bowel movement after 30 minutes to 6 hours.

    Mixtures: Urin D/S, Uretron D/S
  5. Drug

    Tezepelumab

    go.drugbank.com/drugs/DB15090
    ApprovedInvestigational

    [A243764, A243769] Thymic stromal lymphopoietin (TSLP), an innate pleiotropic IL-2-family cytokine, has emerged as a key upstream regulator of chronic inflammation across asthma endotypes.

  6. Drug

    Pafolacianine

    go.drugbank.com/drugs/DB15413
    ApprovedInvestigational

    [A242572] On November 29, 2021, the FDA approved pafolacianine as an adjunct imaging agent for intraoperative identification of malignant lesions in adult patients with ovarian cancer.

  7. Drug

    Idecabtagene vicleucel

    go.drugbank.com/drugs/DB16665
    ApprovedInvestigational

    [A232563] Multiple myeloma is typically treated with an immunomodulatory agent like [lenalidomide],[A232593] a proteasome inhibitor like [bortezomib], or an anti-CD38 monoclonal antibody like [isatuximab … [A232558] The chimeric antigen receptor of idecabtagene vicleucel includes an anti-B-cell maturation antigen scFv-targeting domain, CD3ζ T-cell activation domain, and 4-1BB costimulatory domain.

  8. Drug

    Lisocabtagene maraleucel

    go.drugbank.com/drugs/DB16582
    ApprovedInvestigational

    [A228493] Despite the adverse reactions, the majority of patients given lisocabtagene maraleucel reported an overall increase in quality of life over a 1 year period.

  9. Drug

    Calcifediol

    go.drugbank.com/drugs/DB00146
    ApprovedInvestigationalNutraceutical

    The major circulating metabolite of vitamin D3 (cholecalciferol). It is produced in the liver and is the best indicator of the body's vitamin D stores.

    Synonyms: 25-Hydroxyvitamin D3International brands: De Kai
  10. Drug

    PD-168393

    go.drugbank.com/drugs/DB07662
    Experimental

    PD-168393 is an epidermal growth factor receptor inhibitor.